Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4764531> ?p ?o }
Showing triples 1 to 46 of
46
with 100 triples per page.
- Q4764531 subject Q22230916.
- Q4764531 subject Q8398040.
- Q4764531 subject Q8790354.
- Q4764531 abstract "Anidulafungin (brand names: Eraxis (in U.S. and Russia), Ecalta (in Europe)) is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals. Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005. Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006; it was previously known as LY303366. Preliminary evidence indicates it has a similar safety profile to caspofungin. Anidulafungin has proven efficacy against esophageal candidiasis, but its main use will probably be in invasive Candida infection; it may also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.".
- Q4764531 atcPrefix "J02".
- Q4764531 atcSuffix "AX06".
- Q4764531 casNumber "166663-25-8".
- Q4764531 chEBI "55346".
- Q4764531 drugbank "DB00362".
- Q4764531 fdaUniiCode "9HLM53094I".
- Q4764531 iupacName "N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2R)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide".
- Q4764531 pubchem "166548".
- Q4764531 thumbnail Anidulafungin_structure.svg?width=300.
- Q4764531 wikiPageWikiLink Q131260.
- Q4764531 wikiPageWikiLink Q204711.
- Q4764531 wikiPageWikiLink Q206921.
- Q4764531 wikiPageWikiLink Q2076617.
- Q4764531 wikiPageWikiLink Q22230916.
- Q4764531 wikiPageWikiLink Q2903964.
- Q4764531 wikiPageWikiLink Q335130.
- Q4764531 wikiPageWikiLink Q3718510.
- Q4764531 wikiPageWikiLink Q407426.
- Q4764531 wikiPageWikiLink Q40936.
- Q4764531 wikiPageWikiLink Q420875.
- Q4764531 wikiPageWikiLink Q5332458.
- Q4764531 wikiPageWikiLink Q578726.
- Q4764531 wikiPageWikiLink Q683881.
- Q4764531 wikiPageWikiLink Q8398040.
- Q4764531 wikiPageWikiLink Q8790354.
- Q4764531 wikiPageWikiLink Q901154.
- Q4764531 atcPrefix "J02".
- Q4764531 atcSuffix "AX06".
- Q4764531 casNumber "166663".
- Q4764531 chebi "55346".
- Q4764531 drugbank "DB00362".
- Q4764531 iupacName "N-[-6-[-1,2-dihydroxy-2-ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.09,13]heptacosan-18-yl]- 4-{4-[4-phenyl]phenyl}benzamide".
- Q4764531 pubchem "166548".
- Q4764531 unii "9".
- Q4764531 type ChemicalSubstance.
- Q4764531 type Drug.
- Q4764531 type ChemicalObject.
- Q4764531 type Thing.
- Q4764531 type Q8386.
- Q4764531 comment "Anidulafungin (brand names: Eraxis (in U.S. and Russia), Ecalta (in Europe)) is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals. Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005. Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006; it was previously known as LY303366.".
- Q4764531 label "Anidulafungin".
- Q4764531 depiction Anidulafungin_structure.svg.